Compare SOTK & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | RNXT |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1M | 79.4M |
| IPO Year | 1995 | 2021 |
| Metric | SOTK | RNXT |
|---|---|---|
| Price | $5.78 | $1.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $7.50 | $7.13 |
| AVG Volume (30 Days) | 44.3K | ★ 1.1M |
| Earning Date | 10-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 20.00 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $20,909,315.00 | $1,123,000.00 |
| Revenue This Year | $3.73 | $244.84 |
| Revenue Next Year | $10.38 | $195.26 |
| P/E Ratio | $115.80 | ★ N/A |
| Revenue Growth | 1.97 | ★ 2511.63 |
| 52 Week Low | $3.40 | $0.70 |
| 52 Week High | $6.24 | $2.59 |
| Indicator | SOTK | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 69.22 | 47.41 |
| Support Level | $4.59 | $1.55 |
| Resistance Level | $6.24 | $1.80 |
| Average True Range (ATR) | 0.33 | 0.12 |
| MACD | 0.15 | -0.05 |
| Stochastic Oscillator | 86.92 | 22.86 |
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.